Evaluation of indomethacin by a controlled, cross-over technique in 30 patients with ankylosing spondylitis.
A clinical evaluation of indomethacin employing a controlled, cross-over technique with an inert placebo was undertaken in 30 patients with ankylosing spondylitis. Patients were studied for the frequency and dose relationship of side effects and for the subjective response of morning stiffness, chronic spinal pain, acute exacerbations of pain and peripheral arthralgia. Objective evaluation assessed measured change in movements of the cervical and lumbar spines, in chest expansion and in the range of movement of involved peripheral joints.Evaluation of the results indicated that a significant number of patients experienced side effects in the form of headache and dizziness while receiving indomethacin in doses above 150 mg. per day. Many other side effects reported by the patients were not found to occur at a statistically significant level. The significance of pulmonary infections encountered in three patients was reviewed. Relief of chronic spinal pain and peripheral arthralgia occurred in 14 and 16 patients, respectively (p < 0.05). Relief of morning stiffness and acute exacerbations of pain, and increase in the range of movement of any of the segments of the spine or the involved peripheral joints were not significant (p > 0.05). Based on the results of this study, it is suggested that the role of indomethacin in the management of ankylosing spondylitis be re-evaluated and that the daily therapeutic dose of this drug which has been heretofore recommended be decreased.
D000469:Alkaline Phosphatase / Q000032:analysis; D000747:Anemia, Hypochromic / Q000139:chemically induced; D001219:Aspartate Aminotransferases / Q000097:blood; D001241:Aspirin / Q000008:administration & dosage; D002493:Central Nervous System Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000209:etiology; D004342:Drug Hypersensitivity; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage* / Q000009:adverse effects; D010653:Phenylbutazone / Q000008:administration & dosage; D010919:Placebos; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D013256:Steroids / Q000008:administration & dosage; D014717:Vertigo / Q000139:chemically induced; D005719:gamma-Globulins / Q000032:analysis
D010919:Placebos; D013256:Steroids; D005719:gamma-Globulins; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase; D010653:Phenylbutazone; D001241:Aspirin; D007213:Indomethacin